CD11b is a novel alternate receptor for CD154 during alloimmunity.

ABSTRACT: Antagonism of the CD154/CD40 pathway is a highly effective means of inducing long-term graft survival in preclinical models. Using a fully allogeneic murine transplant model, we found that CD154 blockade was more effective in prolonging graft survival than was CD40 blockade, raising the possibility that CD154 binds a second receptor. To test this, we queried the impact of CD154 antagonism in the absence of CD40. Data indicated that anti-CD154 functioned to reduce graft-infiltrating CD8⁺ T cells in both WT and CD40^-/- hosts. Because it has recently been reported that CD154 can ligate CD11b, we addressed the impact of blocking CD154-CD11b interactions during transplantation. We utilized a specific peptide antagonist that prevents CD154 binding of CD11b but has no effect

SUBMITTER: Liu D 

PROVIDER: S-EPMC7395865 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature